← Back to Search

Transitional Care for Liver Disease (TLC Trial)

N/A

Recruiting

Led By Eric Orman, MD

Research Sponsored by Eric Orman

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days after discharge of initial hospitalization at which the participant was enrolled in the study and 90 days after discharge of initial hospitalization at which the participant was enrolled in the study

Awards & highlights

TLC Trial Summary

This trial is testing if a care model can help reduce hospital readmissions & improve quality of life for patients with advanced liver disease.

Who is the study for?

This trial is for adults over 18 with advanced liver disease, either cirrhosis or acute alcoholic hepatitis. Participants must have had a recent complication from their condition and be ready to leave the hospital soon. They need to speak English or Spanish, be able to follow up after discharge, and not be in hospice care or listed for a liver transplant with a high MELD-Na score.Check my eligibility

What is being tested?

The study tests the Transitional Liver Clinic (TLC), aiming to reduce hospital readmissions and improve quality of life for patients after they're discharged. TLC provides specialized post-discharge care tailored for individuals recovering from complications associated with advanced liver disease.See study design

What are the potential side effects?

Since TLC involves supportive care rather than medication, side effects are minimal compared to drug treatments. However, there may still be general discomforts related to healthcare visits such as stress or anxiety about medical appointments.

TLC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days after discharge of initial hospitalization at which the participant was enrolled in the study.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days after discharge of initial hospitalization at which the participant was enrolled in the study.

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after discharge of initial hospitalization at which the participant was enrolled in the study. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

30-day hospital readmissions for patients hospitalized with complications of advanced liver disease

Patient satisfaction for patients hospitalized with complications of advanced liver disease via the PSQ 18 questionnaire

Quality of life for patients hospitalized with complications of advanced liver disease via Promis 29+2 survey

Secondary outcome measures

90 day mortality

Days alive out of the hospital

Hospital readmissions

+1 more

TLC Trial Design

2Treatment groups

Active Control

Group I: Transitional Liver Clinic (TLC)Active Control1 Intervention

Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.

Group II: Control groupActive Control1 Intervention

Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Eric OrmanLead Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH

2,359 Previous Clinical Trials

4,313,592 Total Patients Enrolled

Eric Orman, MDPrincipal InvestigatorIndiana University

1 Previous Clinical Trials

80 Total Patients Enrolled

Media Library

Transitional Liver Clinic (TLC) Clinical Trial Eligibility Overview. Trial Name: NCT05733832 — N/A

Liver Disease Research Study Groups: Transitional Liver Clinic (TLC), Control group

Liver Disease Clinical Trial 2023: Transitional Liver Clinic (TLC) Highlights & Side Effects. Trial Name: NCT05733832 — N/A

Transitional Liver Clinic (TLC) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05733832 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the concentration of medical facilities conducting this research within city limits?

"The study is currently being conducted in 4 separate sites, which are situated in Indianapolis, Ann Arbor and Philadelphia as well as an additional 4 cities. To make the experience more convenient for participants, it's advised that they select a clinic near to them."

Answered by AI

Is the enrollment period still open for participants?

"According to clinicaltrials.gov, this study is no longer searching for participants, as the last edit was on February 8th 2023. Despite that, there are still 257 other medical trials open and actively enrolling patients presently."

Answered by AI

What are the end goals of this scientific exploration?

"This medical trial was designed to evaluate the quality of life for patients hospitalized with advanced liver disease, as assessed 30 days after initial hospitalization. Secondary objectives encompass 90 day mortality rate, number of days alive out of the hospital and potential re-admissions over study duration; all data will be sourced from either patient self-reports or local medical records."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease

Eric Orman 2023. "A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05733832.

All > Liver Disease